Brooks Rahmer
Contatto Relazioni con gli Investitori presso ROCKET PHARMACEUTICALS, INC.
Profilo
Brooks Rahmer is currently the Head-Investors Relations Contact at Rocket Pharmaceuticals, Inc. He previously worked as the Investor Relations Contact at MyoKardia, Inc. from 2019 to 2021.
Posizioni attive di Brooks Rahmer
| Società | Posizione | Inizio |
|---|---|---|
| ROCKET PHARMACEUTICALS, INC. | Contatto Relazioni con gli Investitori | - |
Precedenti posizioni note di Brooks Rahmer
| Società | Posizione | Fine |
|---|---|---|
| MYOKARDIA, INC. | Contatto Relazioni con gli Investitori | 01/01/2021 |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| ROCKET PHARMACEUTICALS, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
MyoKardia, Inc.
 MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA. | Health Technology |
- Borsa valori
- Insiders
- Brooks Rahmer
